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A decade ago, a group of former presidents from Latin America, headed by Fernando Henrique Cardoso of 
Brazil, César Gaviria of Colombia, and Ernesto Zedillo of Mexico, met with leaders from Europe and the United 
Nations to establish the Global Commission on Drug Policy. Before that, drug policy was rarely considered a 
top priority by heads of state and government. Even in the face of contradictory evidence, most agreed with 
the simplistic view that drugs were a scourge to be swept under the carpet by aggressive law enforcement. 
By 2011, five years after 2006 Mexico’s militarized war on drugs, a startling number of people had been killed, 
driven from their homes or had disappeared. These hard facts became a catalyst for action. Clearly it was 
states, elected authorities, and their own policies that were creating harm under the guise of preserving health. 
Other eminent personalities – from Ghana, Norway, Pakistan, Switzerland, the United Kingdom and the United 
States – stood alongside the former presidents of Brazil, Mexico and Colombia to speak out against the 
entrenched global drug policy regime.
Ten years later, the taboo on openly opposing that global regime has been well and truly broken. There has 
been a range of reforms at national and sub-national level. More and more countries are decriminalizing 
personal use, adopting innovative approaches based on public health and legalizing formerly banned 
substances. Recognition is growing that globally sanctioned repressive policies are more detrimental than 
occasional drug use. These reforms are shining islands in a dark sea of repression.
At the same time, though, the global drug regime’s policy of prohibition remains in place. Almost no new 
jurisdiction has abolished the death penalty for drug-related crimes. Extrajudicial killings for drug-related 
activities have been openly promoted. Overcrowded prisons incarcerate many people convicted of drug 
offences who have caused no harm to anyone. Mandatory abstinence-only drug treatment is still being 
imposed. And organized crime has increased its control on the market and on the small players caught in it.
Thus, in the last decade, there were impressive reforms, but not enough to dislodge the overall punitive 
paradigm.  Decades of stigma, pseudoscience and racism will not be undone overnight. Yet cracks in the old 
structures are appearing. 
Over the past decade, the Global Commission has renewed itself, guided global debates and added members 
from all over the world. With the same determination, it carries on the advocacy and the legacy of the founding 
Commissioners of 2011 and honours the memory of those who have passed. 
In 2011, the Commission began exposing the harmful effects of drug prohibition policies, and the 
disproportionate cost of law enforcement and repressive criminal justice on marginalized, stigmatized and 
irrationally punished people. In 2014, the Commission shared five pathways towards drug policies that work, 
providing governments with a pragmatic plan to reform their policies and to uphold the wellbeing and dignity 
of people. The Commission has published a significant literature on perceptions of drugs, the flaws of the 




This report marks ten years of the Commission’s work, analysis and recommendations. The Commissioners 
are unequivocal in stating that the international framework, based on the 1961, 1971, and 1988 conventions 
on drugs, is itself the problem. In general, the world looks to international law to support the achievement of 
humanity’s fundamental aspirations, including of human rights for all. Yet in drug policy, international law itself 
bears much of the responsibility for the world’s failure to address drug use in a rational and humane way. By 
unfairly deciding what is legal and what is not without sound scientific assessment, and by imposing a universal 
repressive model, international drug law stands in the way of much-needed reform. It is time to review the 
three international drug control conventions, in order to build a serious, modern and responsible drug control 
framework centered on human rights and based on results.
This report is a blueprint for advocacy of reform. It highlights the changes that have occurred in the past 
decade and puts forward necessary changes for the coming decade. While change is happening, tremendous 
hurdles still lie ahead. As long as prohibition prevails as the global drug control paradigm, it makes reform 
challenging. But alongside health and social workers, law enforcement officials and policymakers, millions of 
people who use drugs, and other communities and people directly and indirectly concerned, the Commission 
remains committed to ending prohibition and promoting drug laws and policies that are based on reason, 
evidence and human rights. 
Helen Clark  
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BREAKING TABOOS: A DECADE OF PROGRESS
Unravelling the costly, ineffective, and punitive approach to drug policy was the first step in breaking the taboo 
and vital to the future of global drug policy reform. 
Bringing human rights to the core of drug policy debates has been an important development of the past 
decade. Around the world, enforcing repressive drug laws has led to repeated environmental and human 
rights violations. A truly human rights-centred drug policy ought to protect human autonomy, reduce the harm 
of drug use and curb the violence and exploitation produced by the illegal trade. But today’s international law 
excels at undermining autonomy and amplifying the harm of drug use, while transnational criminal networks 
reap profits. In 2008, the UN Special Rapporteur on the right to health (current Global Commissioner Anand 
Grover) described the international drug control and human rights systems as behaving as if they existed in 
two parallel universes. While these two universes are finally intersecting, international drug law continues to be 
a central barrier to global reform.
While UN drug conventions have established global minimum requirements for drug law enforcement, they 
do not impose limits on the level of repression that states may apply. The three UN conventions, which almost 
every UN member state has ratified, include special articles on the “application of stricter national control 
measures,” which allow countries to adopt more severe punishments if they are deemed “necessary” for 
the “protection of the public health or welfare.” At the same time, the conventions allow flexibility in the 
implementation of policies related to the criminalization of drug use and possession, since “punishable 
offences” are “subject to [the] constitutional limitations” of each country. Therefore, the decriminalization 
of drug use and possession is possible within the current global framework. The way the conventions are 
currently implemented at national level reflects national political priorities and institutional capacity. 
In some countries, decades of stigmatization and dehumanization of people who use drugs have been 
supported by disproportionately harsh criminal sanctions, judicial corporal punishment and even the death 
penalty. Over the last decade, authoritarian leaders have risen to power by propagating simplistic “tough on 
crime” agendas, demonizing people who use drugs and vowing to exterminate drugs and crime through brute 
force. Mounting a vigorous, organized response to these political drug warriors will be a critical challenge in 
the coming decade. 
Reversing entrenched attitudes will not be easy. An alternative political vision is needed that is capable of 
mobilizing and inspiring disenfranchised sections of the population. Alternative strategies need to reform 
legal and penal systems, and foster informed media and free and active civil society. Most important, people 
who use drugs must be understood as people who deserve respect and support and whose voices need to 
be heard.
In the past decade, there has been significant progress and exciting momentum towards drug policies that 
prioritize harm reduction, innovative and voluntary treatment, decriminalization, and human rights. Parting ways 
with the international status quo, national and sub-national administrations around the world are recognizing 
that drug use is of health and social justice rather than of crime and punishment. 
In recent years, scientific research has highlighted the failures and harms of prohibition, and is playing a 
key role in informing evidence-based strategies that prioritize health and human rights. One of the most 
consequential scientific triumphs of the past decade has been the affirmation of harm reduction. Harm 
reduction is a practice and set of policies premised on respecting personal autonomy while reducing the 
social and health consequences of problematic drug use. Harm reduction accepts the risks and realities of 
drug use, but without judgement or scorn, and helps people to survive drug dependence. Harm reduction 
approaches bring together activists, health workers, social workers, researchers and people who use drugs. 
Such approaches have finally gained political purchase around the world despite deeply entrenched 
ideological resistance to change. 
Helen Clark
Former Prime Minister 
of New Zealand
Chair of the Global Commission
since 2020
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Despite the growing acceptance of harm reduction principles, funding and implementation on the ground still 
lag behind, especially in low- and middle-income countries. Far more resources are still invested in supply-side 
drug enforcement strategies than in life-saving harm reduction interventions. 
While syringe programs and opioid agonist therapies are available in most countries across North America 
and Western Europe, these core harm reduction interventions are only slowly being implemented in other 
regions as pilot projects. Overall, they are severely under resourced, overstretched to meet the demand and 
remain unreachable for the vast majority of people dependent on drugs. Supervised consumption sites, which 
monitor people who consume drugs to prevent fatal overdoses and other health conditions, are only operating 
in Australia and Canada and a handful of countries in Europe.
Science has prevailed over ideology in several recent scheduling decisions at the United Nations level. 
Substances including tramadol, ketamine and the khat plant were spared the fate of being internationally 
prohibited. This is largely due to scientific assessments by the World Health Organization’s Expert Committee 
on Drug Dependence, which has repeatedly recommended against scheduling substances deemed medically 
essential, based on a pragmatic balance of health risks and benefits. For a decade, the Global Commission 
has been advocating that this very approach – a careful assessment of a substance’s health risks – is applied 
to all drugs.
Rigorous research and analysis also demonstrate the continued expansion and diversification of the drugs 
market, especially the production of new and highly potent synthetic drugs like illegally manufactured fentanyl. 
This undeniable fact has eroded confidence in the old UN slogan “A drug-free world – we can do it”. Adapting 
to reality, Europe, the Americas and Africa are slowly but steadily abandoning “drug-free” language.
Research is also shifting public opinion to a more objective outlook. In 1973, only 16% of Americans favoured 
cannabis legalization. As of 2021, 18 states have legalized cannabis for non-medical use, 91% of U.S. adults 
believe that cannabis should be legal for medical or non-medical use, and 60% believe cannabis should be 
legal for both medical and non-medical use, a dramatic reversal of opinion. Following in the footsteps of 
Uruguay, Canada and a growing number of U.S. states, cannabis policy is on the move across the Americas 
and the Caribbean, and breakthroughs in reform are imminent in Europe as well. 
The reforms of the last decade are a promising but fragile development. International drug law remains a 
barrier to building a future with humane and rational drug policy. 
The current drug control strategy, solidified by international consensus sixty years ago, is in desperate need of 
a new paradigm grounded in evidence, justice and human rights. We outline in Part III how such a paradigm 
can be put into practice.
COVID-19 and harm reduction: challenge or opportunity?
The COVID-19 pandemic has highlighted massive disparities in the delivery of harm reduction services around 
the world, and directly affected health and right to health of millions of people dependent on drugs. During 
the first phase of the pandemic, lockdowns disrupted drug trafficking and the illegal market, hindered the 
delivery of harm reduction services, brought lower quality drugs onto the illegal market and took an economic 
toll on consumers. The response by countries varied. According to Harm Reduction International, 47 countries 
considered people dependent on drugs vulnerable to the virus and home-delivered substitution treatments. 
In the Middle East, by contrast, harm reduction services closed or ran on shorter hours. In some countries, 
organizations that represent people who use drugs played a key role in supporting people dependent on 
drugs and delivering harm reduction services.
As the COVID-19-related economic crisis spreads around the world, the Global Commission fears significant 
budgetary displacements, in the coming years, that may leave life-saving harm reduction services behind. The 
Commission firmly calls for health system strengthening strategies to include harm reduction as a pillar, and 
on authorities to implement their national responses to problematic drug use by providing at-scale services 
for people who need them. 
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Volunteers from the Andrey Rylkov Foundation distribute free needles 
and condoms to more than 3500 people in Moscow. The Foundation 
is one of the only grassroots organizations that provide such services 
in the Russian Federation, the country with one of the world’s largest 
population of people who inject drugs.
Photography © Max Adveev
Across the world, reforms are taking hold
While drug policy reforms were limited and scattered over the last decade, countries on every continent have 
significantly advanced their drug policy debates and overhauled policy:
In 2013, Uruguay was the first country in the world to legalize the recreational 
adult use of cannabis for its citizens and residents. In 2017, Canada allowed 
its citizens and residents to acquire quality-controlled products through legal 
supply chains. The country has developed large harm reduction services to 
tackle the acute opioid-related overdose crisis, providing emergency funding 
and policy support to recovery at different governance levels. In 2015, 
Mexico adopted regulatory changes to its prescription and dispensing of 
opioid analgesics, allowing physicians to use electronic prescription systems 
for opioid medicines and making it mandatory for medical schools to 
include palliative care in their curricula. The same year, Jamaica introduced 
a decriminalization model of cannabis use, diverting consuming populations 
from the criminal justice system. 
In 2019, Thailand was the first country in the region to legalize medical 
uses of cannabis. In 2020, Malaysia reviewed its death penalty sentencing 
guidelines, allowing judges more discretion and lifting the mandatory nature 
of the sentence in case of serious crimes, including those related to illegal 
drugs.
In 2019, New Zealand introduced a decriminalization model allowing law 
enforcement discretion towards personal drug use and possession. In 2021, 
the country introduced drug checking in festivals and party milieus. The New 
Zealand population narrowly rejected a model of adult cannabis legalization 
by referendum in 2020.
In 2017, Tunisia allowed judges discretion in cannabis-related cases, releasing 
them from having to hand down a mandatory one-year imprisonment sentence. 
In South Africa, the Supreme Court legalized cannabis consumption in the 
private sphere in 2018. In 2020, Ghana introduced the first decriminalization 
model for drug use and possession in Africa, allowing the judiciary to lift 
criminal sanctions on consumers for occasional use. 
In 2020, the Netherlands introduced legal production of cannabis as an 
experimental pilot project in ten cities. In 2021, Luxembourg announced 
legalization of adult cannabis use and cultivation within home settings, while 
Switzerland adopted a framework introducing pilot projects of cannabis 
legalization for adult recreational use. Several European countries have 
adopted drug checking services, which reduce harm to users by allowing 
them to find out the content and purity of substances they intend to consume.
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Global availability of Opioid Agonist Therapy (OAT) in prisons and in communities
Source: Harm Reduction International, 2020
OAT available in the community
OAT available in the community and prison
OAT not available
Countries accross the world that have adopted some form of drug use decriminalization
Opening of the Second Session of UN 
Commission on Narcotic Drugs, Lake 
Success, New York, 1947. 
© UN Photo
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RECIPE FOR FAILURE: THE INTERNATIONAL 
DRUG CONTROL FRAMEWORK 
In 1961, member states of the United Nations convened in New York to agree on the Single Convention 
on Narcotic Drugs. They wanted to recognize that “narcotic drugs” are indispensable to relieve pain and 
suffering, and therefore must be made available for medical use, but also declared that what they considered 
problematic drug use “constitutes a serious evil for the individual and is fraught with social and economic 
danger to mankind.” The goal of the UN convention was thus two-fold: to ensure access to controlled 
substances for medical purposes around the world while rendering any other access illegal, and establish a 
repressive system through prohibition and criminal law. 
Ten years later, President Richard Nixon of the United States officially launched the “war on drugs,” declaring 
an “all-out, global war on the drug menace”, pledging to “fight it with all of the resources at our command.” 
The 1961 Convention, complemented by the 1971 and 1988 conventions, is still in place, and the evidence is 
unequivocal: the international approach to controlling drugs has failed to achieve either of its foundational 
objectives. Despite decades of costly drug enforcement, the supply and production of illegal drugs continues 
to flourish, as does the number of people who use drugs around the world. Meanwhile, much of the world 
still has little to no access to essential controlled medicines. The deep roots of oppressive social control still 
pervade the international drug control regime. 
The laudable goal of ensuring humankind’s access to pain relief quickly took a back seat to an emphasis on 
criminal law enforcement and interdiction, setting decades of military adventurism into motion.
In the context of access to essential controlled medicines, recognition has grown that both legal supply and 
demand must be increased to ensure that all people have access to health care services and humane treatment. 
However, more than 80% of the world’s population, mostly living in low- and middle-income countries, still 
lack access to controlled drugs for pain relief, anesthesia, drug dependence, maternal health, mental health, 
neurology, respiratory distress and palliative care. “The amount of morphine available per person and per 
country is still infinitesimally small to non-existent in many developing countries, particularly in South Asia and 
in Africa”, according to the 2020 World Drug Report. Strict international controls have left millions of people 
around the world suffering with untreated pain. 




























Source: Knaul, F., Bhadelia, A., Rodriguez, N., Arreaola-Ornelas, H., Zimmermann, C. "The Lancet Commission on Palliative Care and Pain Relief —
findings, recommendations, and future directions", The Lancet, March 2018.
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The international community likes to repeat the mantra that the UN conventions are the cornerstones of drug 
control. But this normative framework and the institutional architecture it established lead to ineffective and 
harmful drug control and pose major obstacles to fundamental drug policy changes. 
Over the past decade, strides have been made in changing the narrative on drugs and incremental steps have 
been taken to place health, human rights and development considerations more prominently on the UN drugs 
policy agenda. This has resulted in slowly overcoming the compartmentalized approach to drug control and 
challenging the dominant role of the UN drug institutions in this complex policy issue. This has happened 
both at the UN member states level through the negotiated outcome of the UN General Assembly Special 
Session in 2016 and within the UN system itself – the secretariat, agencies, funds and programmes – through 
the adoption by the UN Chief Executive Board of the Common Position on Drugs. Nevertheless, because of 
entrenched bureaucratic interests and the consensus-driven nature of diplomatic negotiations, these changes 
faced considerable resistance and are not much implemented in practice. 
As the long and needlessly fractious debate to allow cannabis’ medical use has recently shown, an organized 
bloc of countries at the United Nations resists any change to drug laws. Some of these countries, especially in 
Eastern Europe, Asia and the Middle East, have long been marginalized within the international drug control 
system, which was built at times of decolonization or reconstruction. Today, the roles have flipped: these 
countries fiercely defend the “integrity of the treaty system” and oppose meaningful drug policy reform, when 
countries who originally sponsored it increasingly consider it as a straitjacket they no longer care to wear. 
International law does not allow for any non-medical or non-scientific uses of scheduled drugs. Meanwhile, those 
countries that organize a regulated cannabis market for non-medical use (Canada, Uruguay and 18 U.S. States) 
or are considering doing so (Mexico, the Netherlands, Luxembourg and Switzerland) are seen to be in direct 
conflict with their international obligations. International law thus creates an obstacle for countries that wish to try 
their own domestic drug policy reforms, and who do not want to create a precedent of being in default of their 
international obligations or of eroding international consensus, which is pivotal in every other field. 
International law governing access to essential controlled medicines
The World Health organization included 12 medicines that contain internationally controlled substances in 
its Model List of Essential Medicines. These medicines should be available to anyone who needs them, since 
states have a commitment to ensure controlled medicines are made available under international drug control 
law and international human rights law. 
Though several others factors impose barriers to access, including weak healthcare systems, pricing and a 
lack of training of clinicians, the international drug control regime is mainly responsible for perpetuating the 
continual undersupply of controlled medicines. This scarcity is due to the prioritization, by governments and 
UN bodies alike, of preventing the diversion of controlled substances for illegal purposes over ensuring access 
for medical and scientific needs.
The opioid-driven overdose crisis in the United States has shown the perverse effects of lax regulation of 
access to controlled substances. With its call to modernize the international normative framework, the Global 
Commission recommends a complete transfer of the access to controlled medicines to health authorities 
while safeguarding the continuity of both supply and control. Such a reform has the potential, by separating 
the processes of medical and non-medical uses at the technical and political levels, to address the chronic 
shortages of controlled medicines in low- and middle-income countries and help reduce the overconsumption 
of prescribed drugs in high-income countries.
15
By consuming illegal drugs, an estimated 270 million people breach international law every year. Hundreds 
of thousands of others produce plant-based or synthetic drugs at small or large scale, in cities or in rural 
areas, from high-income to low-income countries. Massive defiance of the law erodes fundamental adhesion 
to the rule of law. When laws are ignored on such a scale in any jurisdiction, they are usually reviewed and 
modernized. But when it comes to drug laws, their inability to adapt to societal needs is ignored and, if 
anything, they are enforced with additional zeal through even more repression, thereby causing more harm 
while feeding the cycle of defiance. 
Entrenched problems such as the lack of political leadership and conflicting views between member states at 
the United Nations will not be resolved any time soon, but recognizing the untenable contradictions at play is a 
first step toward a resolution. True reform will not arrive until the outmoded drug conventions are modernized by 
being rebuilt from scratch.
Reform scenarios and leadership 
During the Americas Summit in Cartagena, Colombia, in 2012, then President and current Global Commissioner 
Juan Manuel Santos provided the first political space at head of state level to debate the negative 
consequences of the “war on drugs” in the Americas. 
One of the main successes of the summit was the commissioning of a study on the consequences of current 
repressive policies, and the recommending of new approaches to drug policy. In 2013, the Organization of 
American States published its report Scenarios for the Drugs Problem in the Americas 2013-2025. 
The report included future scenarios for global drug policy, including one where an individual state challenges 
the existing drug control system and ultimately forces the issue of treaty reform to be discussed at the 2016 
UN General Assembly Special Session on drugs.
The scenario foresaw a group of like-minded states coalescing in the post-2016 period and producing a 
“Modernizing Drug Control” proposal. The proposal would call for greater flexibility for individual states to 
explore regulatory alternatives to prohibition, while preserving key elements of the existing framework on drug 
production, trade and access to essential medicines. The pressure generated by this reform grouping on the 
existing system ultimately results in the prohibitionist block giving way, and the emergence of a new, more 
flexible single convention on drugs, replacing the existing three conventions. 
The scenario included the emergence of a legally regulated market. It argued that, “assuming well-functioning 
regulatory structures, legalization could reduce many of the negative consequences with which society is most 
concerned, including violence, corruption, and public disorder surrounding drug distribution; the transmission 
of blood-borne diseases associated with shared needles; and the incarceration of hundreds of thousands of 
low-level drug offenders.”
Regrettably, at the UN General Assembly Special Session 2016 the international community decided to ignore 
the challenges to the international norms of drug control, and reconfirmed the three drug conventions as the 
“cornerstone” of international drug policy. UN member states did not suggest modernizing drug control, 
and New Zealand was the only country supporting novel policies and exploration of legal regulation in its 
statement to the UN General Assembly.
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The global prevalence of HIV, HCV and TB among people 
who inject drugs remained relatively unchanged between 
2011 and 2016
±105,000 directly associatedto drug use ±168,000
450,000 drug-related deaths in 2015
1,230 every day
51 every hour
Drug offences and imprisonment
Source: Penal Reform International, Global Prison Trends 2018, and IDPC, Taking Stock: A decade of drug policy
20% are incarcerated 
for drug offences
Non-violent drug offences 
16.6% of all people incarcerated 
(of which 21% - i.e. half a million people – 
for drug use or possession of small quantities)
Global imprisonment
10.35 million
Global state of the war on drugs
in 2018,
269,000,000 




are spent on the war on drugs
the global opium illegal 
production increased by 
950% since 1980
The global drug market’s 
annual turnover is estimated at
$ 500,000,000,000 
Less than 1%
of the laundered drug 
money is seized
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Drug-war related violence drives Mexico murders to record high
Source: Instituto Nacional de Estadística y Geografía
8,867




Total number of homicides
Security, violence and drug policy: an intrinsic link
In 2008, the United Nations recognized that the international drug control regime was resulting in massive 
negative consequences, which it addressed as “unintended”. The first is the existence of the illegal drug 
market, controlled and managed by criminal organizations that depend on violence to define territories, 
counter law enforcement activity, enforce loyalty and punish betrayal. Such violence is exacerbated by policy 
and budgetary displacement, through which governments focus their drug control resources and interventions 
on law enforcement and repression.
Drug control policy has an annual cost of USD 100 billion, concentrated on law enforcement and militarization 
of the response to drug trafficking. The illegal market itself is estimated at USD 500 billion, controlled by 
transnational organized crime, outside of any financial control. Over 50 years of prohibition and enormous 
efforts to eradicate drug production, use and trafficking have not only failed utterly, they have created major 
security problems and fed violence in urban areas. Of the 50 most violent cities in the world, 42 are in Central 
and South America, along the cocaine trafficking route towards the United States.
Imitating her parents, a girl pours coca leaves into 50-pound sacks in 
La Paz, Bolivia. Once filled at ADEPCOCA (Association of Coca Leaf 
Farmers), the sacks are distributed at several markets around the city. 
The leaves are sold by the pound to consumers who chew on the leaf 
or manufacture products like wine, cookies, bread and medicines.  
© Carlos Villalon
19
RECIPE FOR SUCCESS: A NEW DECADE TO 
DISMANTLE PROHIBITION 
Legal regulation of all drugs is the ultimate goal that the Global Commission is pursuing, building on recent 
progress in harm reduction, treatment of drug dependence, access to controlled medicines, and decriminalization 
models. 
The Global Commission argues that options for legal regulation should be explored for all psychoactive 
substances. Regulation means not only protecting the health and safety of the end-consumer, but also creating 
a supply chain with strict controls for potency, quality and access. Regulation ultimately requires the boldness 
to build a world that does not yet exist.
In its 2018 report Regulation: The Responsible Control of Drugs, the Global Commission proposed a regulation 
model – a system of rules for governing the production, supply and use of drugs: “Regulation brings state 
control into a market sphere where there was none. It establishes a clearly defined role for enforcement 
agencies in policing compliance in any new regulatory framework.”
In terms of crime and public health, international prohibition leaves drug markets occupying the worst of both 
worlds: organized criminal groups reap all the profits, while consumers are left navigating criminalized and 
stigmatized markets where they risk purchasing impure, adulterated substances that can cause serious health 
consequences. 
The cannabis precedent has opened the door to other models of regulation. 
In November 2020, Oregon became the first U.S. state to decriminalize the consumption of all drugs and the 
first jurisdiction in the world to lay out plans for regulating the use of psilocybin, the psychoactive compound in 
“magic mushrooms”, in certified therapeutic settings. As psychedelic drugs undergo rigorous research trials, 
debates about their regulation will continue to grow louder. The international community can either remain a 
roadblock to innovative policy reform or take a bold stance to promote health and well-being. 
Many contentious questions about regulating psychoactive substances can be answered by looking at existing 
legal markets for cannabis and for mild herbal stimulants, like the coca leaf, kratom and khat. 
Regulation reduces harm to health and societies
Prohibition Decriminalization














DIFFERENT DRUGS DIFFERENT DEGREES OF REGULATION 
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The same balance of risks applied to legal, pharmaceutical “medicine” must also be applied to “drugs.” 
This arbitrary binary distinction between “drugs” and “medicine”, and between chasing an illegal high and 
relieving painful suffering, has been a fatal flaw of international drug law since its inception 60 years ago. 
It is irrational to prohibit most substances outright and leave others, like the coca leaf, in a legal twilight zone, 
where under international law it is still controlled as strictly as cocaine. As exemptions and regulated markets 
become more numerous around the world, laws that regulate international trade must adapt to the new reality. 
Nowhere is this fact clearer than in the contemporary psychedelic drug renaissance. A wave of scientific research 
has examined the potential therapeutic uses of psilocybin (magic mushrooms), DMT (dimethyltryptamine) 
and MDMA to treat trauma, depression and other mental health disorders. 
One of the most complex challenges of the next decade identified by the Global Commission is the influence 
of for-profit interests in emerging legal drug markets. How can drug markets be legally regulated without 
promoting consumption, which can undermine public health and prevention efforts? And how can new markets 
ensure that small actors dependent on the illegal drug economy today are brought along in the transition, 
instead of losing their livelihood and falling into extreme poverty or being pushed underground to other 
criminal activities in order to survive? 
Unlike the early days of alcohol and tobacco, responsible regulation places restrictions on advertising, age 
limits for use, and type and contents of products. Such policies are becoming the norm in the majority of 
cannabis regulating jurisdictions. 
An equally important concern is the exclusion of people and communities previously supplying the illegal 
market. For-profit cannabis companies from high-income countries are aggressively competing to capture the 
multibillion-dollar global cannabis market. To protect small-scale farmers within the current overheated and 
corporate-driven market, governments in low- and middle-income countries need to reform drug laws to offer 
their citizens a better framework within which to defend their interests. These need to include the protection 
of traditional farming and historical strains, and well-designed legislation and market strategies. 
The inclusion of cannabis in the strictest 1961 drug schedules was done without proper scientific assessment 
and was heavily influenced by prejudices against non-Western cultural usages. The task ahead is to apply 
lessons learned from a history of colonialism and stigma as new markets are being designed that protect 
health, safety and autonomy. 
The foundations of today’s international drug policy consensus are showing cracks and vulnerabilities. Though
drug laws appeared to be written in stone, the last decade has exposed the system’s inherent weaknesses
and imperfections. Winning the next decade will require new drug narratives that have the power to shatter
an era of racism, stigma, and pseudoscience. The world we envisage does not yet exist, but a global reform
movement is laying the first bricks of a new structure built on health, security and human rights.
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Source: David Bewley-Taylor, Martin Jelsma and Sylvia Kay, “Cannabis Regulation and Development: Fair(er) Trade Options for Emerging Legal 
Markets”, International Development Policy | Revue internationale de politique de développement [Online], 2020 | 12, Online since 12 October 2020, 
connection on 07 May 2021.
Ongoing debate on MDMA regulation in the Netherlands
The increasing criminalization of MDMA  – also known as ecstasy or molly –despite the drug’s low risk of harm 
and dependence caused a debate to erupt in the Netherlands over government policy towards the drug. In 
response, an expert panel examined various policy models for regulating MDMA. The interdisciplinary team 
concluded that regulating sales would protect  people’s health, decrease organized crime and environmental 
damage, improve the quality of MDMA products and provide more opportunities for educating drug consumers. 
While the prevalence of MDMA use could initially increase, the authors note that improved consumer health, 
in conjunction with reduced organized crime, would appeal to a broad political coalition. There would also 
be direct and indirect financial gains, not only through sales but also from reduced costs in health care, less 
environmental pollution and lower expenses in drug enforcement. 
The Netherlands’ proposed regulations for MDMA carry international implications. Because MDMA became a 
Schedule I controlled substance under the UN conventions in 1986, the Netherlands’ MDMA model includes 
the “inter se” option to modify international treaties under Article 41 of the 1969 Vienna Convention on the 
Law of Treaties. In the absence of a consensus on regulating MDMA sales, a group of two or more like-minded 
states could reach agreement among themselves that permit the production and trade of such scheduled 




In the coming decade, the movement to end repressive drug policies must challenge entrenched “tough on 
crime” agendas on the world stage. Now is the time to offer a compelling alternative roadmap that materially 
improves people’s lives while preventing drug-related violence and organized crime. 
A new international drug control strategy is needed that allows national and local governments to test drug 
regulation models that protect the health and safety of citizens and diminishes the power, profits and violent 
reign of transnational criminal networks. 
Success in the coming decade will hinge on the extent to which the global reform movement can organize and 
unite behind a positive agenda that delivers a healthy, sustainable future with economic opportunities for all. 
The organizing principles of the global reform agenda include: 
•	 decriminalizing drug use and possession for personal use, 
•	 ensuring access to essential controlled medicines, 
•	 investing in prevention of drug use, 
•	 providing non-compulsory accessible treatments and harm reduction services, 
•	 implementing alternatives to incarceration for small-scale nonviolent actors of the illegal market, and 
•	 moving towards full regulation of all drug markets fairly protecting the marginalized and vulnerable. 
To deliver a drug policy fit for the 21st century, we urgently and strongly call on governments to:
Promote national legal frameworks and practices in 
accordance with human rights norms
  a Put people’s health and safety first 
 Ensure full access to harm reduction services, drug dependence treatment, and controlled 
essential medicines for pain relief and palliative care by providing sufficient resources in 
national budgets and international development aid. Invest in research on innovative harm 
reduction models for stimulants and new psychoactive substances. 
   b Put human dignity and the rule of law first
 Decriminalize drug use and possession for personal use, end police violence and harassment and 
ensure fair process and proportionality of sentences, including the abolition of the death penalty. 
   c Enhance inclusion, equity and non-discrimination in policies by involving all 
concerned stakeholders in policymaking, including people who use drugs and small-scale 





Mandate the World Health Organization to ensure adequate 
access to essential controlled medicines and scientific 
assessment of substances
Transfer the mandate of the International Narcotics Control Board – including ensuring 
supply of and access to essential controlled medicines, non-diversion towards non-medical 
uses, chemicals control and the estimate systems – from the UN Office of Drugs and Crime 
to the World Health Organization. Such a reform should be complemented by the transfer 
of scheduling decisions to the World Health Assembly, based on scientific assessment of the 
therapeutic evidence of substances by the WHO Expert Committee on Drug Dependence.
Move towards a new international drug control framework 
based on evidence and the latest UN recommendations
 
UN member states that are implementing new approaches to drug control and that are moving 
beyond the international conventions should form a coalition to open a robust and evidence-
based debate about reforming the international drug control framework.
Regulate all drugs
Drugs that are currently prohibited should be regulated. The process to achieve regulation 
of drugs should be cautious, incremental and evidence-based that protects and promotes 
human rights, public health, sustainable development, peace and security. The process should 
engage civil society and communities, including people who use drugs, youth, cultivators and 
small-scale actors in the illegal market. Particular attention should be paid to the tensions 
between public health and commercial interests.
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Trends in the areas of the Global Commission's five pathways
Pathway 1: Put people’s health and safety first
Despite increased awareness of the efficiency of harm reduction and wider endorsement of 
some services such as drug checking, progress made is fragile and harm reduction remains 
largely underfunded. 
Pathway 2: Ensure access to controlled medicines
The issue has gained in visibility at the UNGASS 2016 Outcome Document, reiterated in 2019 at 
the CND Ministerial Declaration, and with a more active WHO’s Expert Committee on Drug 
Dependence (ECDD). That said, almost no progress has been made to ensuring access to 
essential controlled medicines for the 5 billion people living in countries with little or no access 
to palliative care or pain relief. In addition, at least eight countries continue to ban methadone 
and buprenorphine.  
Pathway 3: End criminalization and incarceration of people who use drugs
In 2019, the United Nations Common Position on Drugs endorsed the decriminalization of drug 
use. Over 26 jurisdictions in 9 countries have adopted a decriminalization model. 
Pathway 4: Refocus enforcement on organized crime
There is increasing recognition that drug law enforcement targeting people who use drugs and 
low-scale actors of the drug market exacerbates violence and fuels organized crime activities. 
Pathway 5: Regulate all drugs
The United Nations has recognized the medicinal values of cannabis. In addition, more 
countries have adopted cannabis regulation schemes for both medicinal and recreational use.
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GLOBAL COMMISSION ON DRUG POLICY
The purpose of the Global Commission on Drug Policy is to bring to 
the international level an informed, science-based discussion about 
humane and effective ways to reduce the harms caused by drugs and 
drug control policies to people and societies.
GOALS
Review the base assumptions, effectiveness and consequences of the 
“war on drug“ approach
Evaluate the risks and benefits of different national responses to the 
drug problem
Develop actionable, evidence-based recommendations for constructive 
legal and policy reform
